NASDAQ:NTRA - Natera Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $20.49 +0.19 (+0.94 %) (As of 03/22/2019 06:46 AM ET)Previous Close$20.30Today's Range$20.20 - $20.5152-Week Range$8.60 - $29.62Volume558,296 shsAverage Volume723,579 shsMarket Capitalization$1.29 billionP/E Ratio-9.53Dividend YieldN/ABeta1.84 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of approximately 70 laboratory and distribution partners in the United States and internationally. Natera, Inc. has collaboration partnership with Fox Chase Cancer Center to assess customized circulating tumor DNA assay for recurrence monitoring of kidney cancer; and clinical trial collaboration with Neon Therapeutics, Inc. to assess the treatment response to personal cancer vaccine. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California. Receive NTRA News and Ratings via Email Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTRA Previous Symbol CUSIPN/A CIK1604821 Webwww.natera.com Phone650-249-9090Debt Debt-to-Equity Ratio2.28 Current Ratio2.11 Quick Ratio2.32Price-To-Earnings Trailing P/E Ratio-9.53 Forward P/E Ratio-9.15 P/E GrowthN/A Sales & Book Value Annual Sales$257.65 million Price / Sales4.99 Cash FlowN/A Price / Cash FlowN/A Book Value($0.19) per share Price / Book-107.84Profitability EPS (Most Recent Fiscal Year)($2.15) Net Income$-128,150,000.00 Net Margins-49.72% Return on Equity-790.13% Return on Assets-51.80%Miscellaneous Employees975 Outstanding Shares62,790,000Market Cap$1.29 billion Next Earnings Date5/14/2019 (Estimated) OptionableOptionable Natera (NASDAQ:NTRA) Frequently Asked Questions What is Natera's stock symbol? Natera trades on the NASDAQ under the ticker symbol "NTRA." How were Natera's earnings last quarter? Natera Inc (NASDAQ:NTRA) announced its quarterly earnings data on Tuesday, March, 12th. The medical research company reported ($0.51) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.51). The medical research company had revenue of $67 million for the quarter, compared to the consensus estimate of $62.87 million. Natera had a negative return on equity of 790.13% and a negative net margin of 49.72%. View Natera's Earnings History. When is Natera's next earnings date? Natera is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Natera. What guidance has Natera issued on next quarter's earnings? Natera updated its FY 2019 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $275-302 million, compared to the consensus revenue estimate of $287.54 million. What price target have analysts set for NTRA? 7 brokerages have issued twelve-month price targets for Natera's stock. Their predictions range from $20.00 to $41.00. On average, they anticipate Natera's share price to reach $28.4286 in the next year. This suggests a possible upside of 38.7% from the stock's current price. View Analyst Price Targets for Natera. What is the consensus analysts' recommendation for Natera? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natera. What are Wall Street analysts saying about Natera stock? Here are some recent quotes from research analysts about Natera stock: 1. According to Zacks Investment Research, "Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. " (3/21/2019) 2. Canaccord Genuity analysts commented, "We’re positive on the deal, which provides NTRA with $50M of non-dilutive financing upfront, royalties on future BGI revenues, and further decentralization of its testing OUS. We don’t understand why the stock is not up 10-15%+ on this news; regardless, we view this deal as a material positive and would buy NTRA stock here. Natera is one of our top picks for 2019 and trades at just 2.9x Street ’20 revs (below its peak of ~5x just 7 months ago). We reiterate our $25 PT and turn our focus to NTRA’s Q4 call tomorrow night. The deal. Under the 10-year agreement, BGI will pay Natera $50 million in upfront licensing fees and prepaid royalties in Q1. Natera will also receive ongoing royalty payments. Natera will prepay BGI Genomics $6M for sequencing services related to this partnership." (3/11/2019) Has Natera been receiving favorable news coverage? News headlines about NTRA stock have been trending negative recently, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Natera earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Natera's key competitors? Some companies that are related to Natera include ELEKTA AB/ADR (EKTAY), Genomic Health (GHDX), InVitae (NVTA), CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Fulgent Genetics (FLGT), PotNetwork (POTN), Psychemedics (PMD), First Choice Healthcare Solutions (FCHS), OpGen (OPGN) and CBA Florida (CBAI). What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Micron Technology (MU), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN), Aegean Marine Petroleum Network (ANW) and Transocean (RIG). Who are Natera's key executives? Natera's management team includes the folowing people: Dr. Matthew Rabinowitz, Co-Founder & Exec. Chairman (Age 46)Mr. Steve Chapman, Chief Exec. Officer (Age 39)Mr. Michael Brophy, Chief Financial Officer (Age 39)Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 46)Mr. Robert A. Schueren, Chief Operating Officer (Age 57) When did Natera IPO? (NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. Who are Natera's major shareholders? Natera's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (6.32%), Jennison Associates LLC (6.00%), BlackRock Inc. (4.45%), Macquarie Group Ltd. (3.39%), Millennium Management LLC (2.74%) and Peregrine Capital Management LLC (0.86%). Company insiders that own Natera stock include Claremont Creek Partners Fund, Herm Rosenman, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Institutional Ownership Trends for Natera. Which major investors are selling Natera stock? NTRA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Bank of New York Mellon Corp, Kornitzer Capital Management Inc. KS, Regents of The University of California, Nuveen Asset Management LLC, D. E. Shaw & Co. Inc., BlackRock Inc. and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Natera company stock in the last year include Claremont Creek Partners Fund, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Insider Buying and Selling for Natera. Which major investors are buying Natera stock? NTRA stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Thrivent Financial for Lutherans, First Manhattan Co., Foresite Capital Management III LLC, First Trust Advisors LP, Citigroup Inc., Macquarie Group Ltd. and Canada Pension Plan Investment Board. View Insider Buying and Selling for Natera. How do I buy shares of Natera? Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Natera's stock price today? One share of NTRA stock can currently be purchased for approximately $20.49. How big of a company is Natera? Natera has a market capitalization of $1.29 billion and generates $257.65 million in revenue each year. The medical research company earns $-128,150,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Natera employs 975 workers across the globe. What is Natera's official website? The official website for Natera is http://www.natera.com. How can I contact Natera? Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected] MarketBeat Community Rating for Natera (NASDAQ NTRA)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 256 (Vote Outperform)Underperform Votes: 245 (Vote Underperform)Total Votes: 501MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe NTRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/22/2019 by MarketBeat.com StaffFeatured Article: What is the Gross Domestic Product (GDP)?